Milana Dolezal, MD, MSci

Articles

Considering Novel Therapy for HER2+ Metastatic Breast Cancer

April 29th 2022

A summary of sequencing therapy in the HER2+ metastatic breast cancer treatment paradigm followed by excitement for novel therapies under investigation.

Patient Profile 2: 3L Therapy for Triple-Positive mBC

April 29th 2022

Before closing out their discussion on the second patient profile, experts review third-line treatment selection for triple-positive metastatic breast cancer.

Patient Profile 2: Second-Line Therapy for Triple-Positive mBC

April 22nd 2022

Expert perspectives on second-line treatment options available for patients who progress with triple-positive metastatic breast cancer.

Patient Profile 2: Patient with Triple-Positive mBC

April 22nd 2022

Experts discuss the use of frontline therapy in patients with triple-positive metastatic breast cancer.

Patient Profile 1: Sequencing Therapies in HER2+ mBC

April 15th 2022

Shared insights on the use of therapies as a patient progresses with HER2+ metastatic breast cancer, which includes sequencing through T-DM1 [trastuzumab emtansine], tucatinib/capecitabine/trastuzumab, and trastuzumab deruxtecan.

Patient Profile 1: Second-Line Therapy for HER2+ mBC

April 15th 2022

Expert perspectives on the selection of second-line therapy when patients progress with HER2+ metastatic breast cancer.

Patient Profile 1: Frontline Therapy for HER2+ mBC

April 8th 2022

Centering discussion on a patient profile of HER2+ metastatic breast cancer, experts elucidate frontline therapy selection in this setting.

Recent Trial Data in HER2+ Metastatic Breast Cancer

April 8th 2022

Before moving on to the patient profiles, expert panelists review recent clinical trial data that have impacted treatment selection and sequencing in HER2+ metastatic breast cancer.

Selecting and Sequencing Therapy for HER2+ Breast Cancer

April 1st 2022

Shared insight on the optimal sequencing of therapeutic agents for patients undergoing treatment for HER2+ metastatic breast cancer.

HER2+ Breast Cancer: Overview of the Treatment Armamentarium

April 1st 2022

Comprehensive insight on therapeutic classes and agents approved in the setting of HER2+ metastatic breast cancer, with a specific focus on how these therapies fit into current treatment strategies.